Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 36%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Icon has demonstrated a robust performance, highlighted by an 11% sequential increase in gross business awards, driven by successful partnerships with both biotech and large pharmaceutical customers. The company has not only met or exceeded its financial targets following the PRA acquisition but also benefits from a favorable client mix, positioning it well against potential funding challenges. Additionally, as the market for contract research organizations (CRO) continues to grow, Icon is poised to enhance its clinical trial research capabilities, further solidifying its competitive advantage.

Bears say

The analysis indicates a concerning trend in Icon's financial performance, particularly with projected EBITDA margins for 2024 and 2025 now expected to be in the high-19% range, slightly lower than previous expectations of around 20%. Additionally, potential downside risks include a slowdown in clinical trial activity due to pharma reprioritizations, uncertainties in biotech funding, and issues related to the inability to realize revenue synergies from the PRA transaction. Furthermore, external factors such as inflation and a slowdown in pharmaceutical R&D spending pose significant threats to Icon's overall revenue growth and profitability, leading to a negative outlook for the stock.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 36% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $211.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $211.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.